BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 833 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 833 shares of the company’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $27.36, for a total value of $22,790.88. Following the sale, the chief financial officer owned 183,353 shares of the company’s stock, valued at approximately $5,016,538.08. This represents a 0.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Thursday, September 11th, Troy Wichterman sold 1,032 shares of BioLife Solutions stock. The stock was sold at an average price of $26.83, for a total transaction of $27,688.56.
• On Tuesday, August 26th, Troy Wichterman sold 590 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total transaction of $15,009.60.

BioLife Solutions Trading Up 0.9%

BLFS stock opened at $27.66 on Wednesday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -230.48 and a beta of 1.95. The firm has a 50-day moving average price of $25.35 and a 200-day moving average price of $23.36. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The company had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 663 shares during the last quarter. SG Americas Securities LLC raised its stake in BioLife Solutions by 21.6% during the first quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider’s stock worth $437,000 after buying an additional 3,405 shares during the last quarter. Rhumbline Advisers raised its stake in BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock worth $1,901,000 after buying an additional 566 shares during the last quarter. Comerica Bank raised its position in shares of BioLife Solutions by 5.2% in the 1st quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 746 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of BioLife Solutions by 6.2% in the 1st quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider’s stock worth $5,927,000 after acquiring an additional 15,241 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective (up previously from $30.00) on shares of BioLife Solutions in a report on Friday, August 8th. Stephens initiated coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Zacks Research lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.29.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.